+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

  • ID: 4282126
  • SWOT Analysis
  • May 2021
  • 55 pages
  • GlobalData

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Secura Bio Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Epizyme Inc (Epizyme) discovers, develops and markets novel epigenetic therapies for the treatment of cancer and other disorders. The company’s marketed product includes, Tazverik (tazemetostat) is an oral, first-in-class, small molecule inhibitor of the EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. It pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 29, 2021: Epizyme Announces Date of First Quarter 2021 Financial Results
Mar 02, 2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
Feb 23, 2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Secura Bio Inc
Section 1 - About the Company
  • Epizyme Inc - Key Facts
  • Epizyme Inc - Key Employees
  • Epizyme Inc - Key Employee Biographies
  • Epizyme Inc - Major Products and Services
  • Epizyme Inc - History
  • Epizyme Inc - Company Statement
  • Epizyme Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Epizyme Inc - Business Description
  • Other Break-up: Collaboration Revenue
  • Performance
  • Other Break-up: Product Revenue
  • Performance
  • R&D Overview
  • Epizyme Inc - Corporate Strategy
  • Epizyme Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Epizyme Inc - Strengths
  • Epizyme Inc - Weaknesses
  • Epizyme Inc - Opportunities
  • Epizyme Inc - Threats
  • Epizyme Inc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Epizyme Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
  • Apr 29, 2021: Epizyme Announces Date of First Quarter 2021 Financial Results
  • Mar 02, 2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
  • Feb 23, 2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
  • Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
  • Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
  • Nov 06, 2020: Epizyme reports business progress and third quarter 2020 financial results
  • Aug 04, 2020: Epizyme reports business progress and second quarter 2020 financial results
  • May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results
  • Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About Us
  • Contact Us
  • Disclaimer
List of Tables
  • Epizyme Inc, Key Facts
  • Epizyme Inc, Key Employees
  • Epizyme Inc, Key Employee Biographies
  • Epizyme Inc, Major Products and Services
  • Epizyme Inc, History
  • Epizyme Inc, Subsidiaries
  • Epizyme Inc, Key Competitors
  • Epizyme Inc, Ratios based on current share price
  • Epizyme Inc, Annual Ratios
  • Epizyme Inc, Interim Ratios
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Epizyme Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Epizyme Inc, Performance Chart (2016 - 2020)
  • Epizyme Inc, Ratio Charts
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Spectrum Pharmaceuticals Inc
  • Secura Bio Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Johnson & Johnson
  • Daiichi Sankyo Co Ltd
  • Constellation Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll